This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Dr. Martin Madaus To Be Named Chairman And CEO Of Ortho-Clinical Diagnostics (OCD)

Global alternative asset manager The Carlyle Group (NASDAQ:CG) today announced that Dr. Martin D. Madaus will become Chairman and Chief Executive Officer of Ortho-Clinical Diagnostics (“OCD”) subject to the close of Carlyle’s acquisition of OCD from Johnson & Johnson, which is expected in mid-2014. Eric Compton, OCD Worldwide President, will continue with the company following the close of the transaction.

Introduced to OCD today during a global employee meeting, Dr. Madaus said, “I am pleased by the opportunity to join Ortho-Clinical Diagnostics and look forward to working with such a talented group of professionals around the world. I am excited at the prospect of leading the organization through its next phase of growth, driven by new product innovation and geographic expansion. Eric and his team have accomplished great things as part of Johnson & Johnson and I look forward to helping transform OCD into a global diagnostics leader as a standalone entity.”

Eric Compton, OCD Worldwide President, said, “OCD has made strategic investments in research and development programs over the past few years and the Company is poised for continued success in the future. Together with Martin and the team at Carlyle, we believe OCD is positioned to accelerate growth globally through new product introductions.”

Stephen H. Wise, Carlyle Managing Director, said, “As an experienced executive with an exemplary track record of growing businesses, Martin can lead OCD through its transition to an independent company and transformation into a leading diagnostics platform. We believe our long-term partnership with Martin in the in vitro diagnostics industry will create significant value for our investors over the coming years.”

Dr. Madaus is the current Executive Chairman of Quanterix’s Board of Directors. He most recently served as President, Chairman and Chief Executive Officer of Millipore Corp., which was acquired by Merck KGaA in 2010. Before joining Millipore, Dr. Madaus was President, Chief Executive Officer and Head of North American Operations for Roche Diagnostics Corp.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

Chart of I:DJI
DOW 17,545.72 -52.48 -0.30%
S&P 500 2,091.32 -6.72 -0.32%
NASDAQ 5,101.6290 -13.7530 -0.27%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs